Key Summary Points {#FPar1}
==================

**Why carry out this study?**The interaction between different anticoagulants and platelet function is controversial.Direct thrombin inhibitors can paradoxically enhance the risk of cardiovascular events in patients with atrial fibrillation.Different targeting anticoagulants might have opposite effects on platelet aggregation.**What was learned from the study?**There is no influence of dabigatran on pharmacodynamics effects of aspirin on patients with chronic coronary artery disease.Anti-Xa drugs can reduce platelet aggregation.

Introduction {#Sec1}
============

The interaction between anticoagulants and platelet activation is complex. The apparent paradoxical association of anticoagulants use with coronary and/or mechanical heart prothesis thromboses has been previously reported \[[@CR1]--[@CR4]\].

Although the role of anticoagulants in the secondary prevention of recurrent ischemic events after acute coronary syndrome (ACS) and during percutaneous coronary intervention (PCI) in stable coronary artery disease (CAD) is well established \[[@CR5]--[@CR8]\], the possible increase in ischemic coronary events with anticoagulants in different clinical settings is a matter of concern \[[@CR2], [@CR6], [@CR9], [@CR10]\]. In this context, enoxaparin, a low molecular weight heparin (LMWH) with predominant anti-Xa mechanism, was shown to be safe in other studies, without pro-aggregatory effects \[[@CR4], [@CR5], [@CR11], [@CR12]\]. In contrast, previous data on different direct thrombin inhibitors (DTI) suggest elevated platelet-mediated risk of thrombosis. Laboratory data from the phase II PETRO trial have shown that dabigatran increases urinary thromboxane metabolite excretion, indicating a platelet‐activating effect \[[@CR13]\]. Additionally, data from the RE-LY trial, which tested dabigatran versus warfarin in patients with atrial fibrillation (AF), suggested that dabigatran may increase the risk of myocardial infarction (MI) (in comparison with warfarin, HR = 1.35, *p* = 0.07 for the 110 mg dose and HR 1.38, *p* = 0.048 for the 150 mg dose) \[[@CR1]\]. Also, bivalirudin, a parenterally administered DTI, increased the risk of acute stent thrombosis within 24 h in patients with ST-segment elevation MI when compared with heparin plus glycoprotein IIb/IIIa inhibitors \[[@CR6]\]. On the other hand, the efficacy results from the randomized placebo-controlled study of dabigatran in patients with ACS on dual antiplatelet therapy (DAPT) were inconclusive. Although there were numerically more cases of MI in the dabigatran arm in the RE-DEEM study, this finding was not statistically significant \[[@CR14]\].

Thus, we hypothesized that DTI (dabigatran) and anti-Xa inhibitor (enoxaparin) might exert antagonistic effects on platelet aggregation in a population of patients with stable CAD.

Methods {#Sec2}
=======

Study Design, Setting, and Population {#Sec3}
-------------------------------------

This was a prospective, open-label, interventional crossover study conducted at the Heart Institute (InCor/HCFMUSP), University of São Paulo Medical School, in patients with chronic CAD. Patients were retrospectively and randomly selected from the Acute Coronary Disease Unit databank. The population consisted of both genders, of least 18 years of age with CAD on aspirin 100 mg/day. CAD was defined as one or more of the following: previous MI, coronary angioplasty, coronary artery bypass graft (CABG) surgery, or coronary angiography showing obstruction of at least 50% in one major epicardial vessel. The main exclusion criteria were as follows: use for the last 7 days of an orally administered anticoagulant or any other antiplatelet drug aside from ASA, any active bleeding, pregnancy or the lack of a contraceptive method in women of childbearing age, hemoglobin \< 10 g/dL, hematocrit \< 30% or \> 50%, platelet count \< 100,000/mm^3^ or \> 500,000/mm^3^, moderate renal insufficiency (creatinine clearance \< 50 ml/min), PCI during the last 30 days before randomization (or PCI during the last year when drug-eluting stents were used), CABG during the last 90 days, ACS during the last 60 days, active malignant neoplasm, active peptic ulcer disease during the last 60 days or upper gastrointestinal bleeding at any time and AF.

The study was approved by the Institutional Review Board of the Ethics Committee (Comissão de Ética para Análise de Projetos de Pesquisa do HCFMUSP) and was conducted in accordance with the declaration of Helsinki of 1964 and its later amendments. All participants provided written informed consent for both their participation in this study and for its publication. The study was registered at ClinicalTrials.gov (NCT02389582).

Study Procedures {#Sec4}
----------------

Patients were submitted to medical interview and physical examination to assess the eligibility criteria. If selected, blood samples were collected for the evaluation of platelet function and for general laboratory tests at baseline. All patients were assigned to dabigatran (150 mg twice daily) for 5 days, followed by a washout period of 30 days. Next, patients were submitted to enoxaparin (1 mg/kg twice daily) for an additional 5 days. Enoxaparin's choice as the anti-Xa drug was due to its safety and the lack of orallly administered anti-Xa adequate doses for the CAD scenario in Brazil. Platelet function tests were performed at baseline and after both treatments (dabigatran and enoxaparin) (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR4], [@CR5]\].Fig. 1Study design

Multiplate electrode aggregometry (MEA) tests (Dynabyte Medical, Munich, Germany) were performed for whole blood platelet aggregometry. Platelet aggregation was triggered with arachidonic acid (MEA-ASPI test) and thrombin receptor-activating peptide 6 (MEA-TRAP test). Reagent delivery was performed using an automatic pipette, and aggregation was recorded for 6 min. The increase in impedance because of the attachment of platelets to the electrodes was detected for each sensor unit separately. Aggregation measured by MEA was quantified as the area under the aggregation curve \[AUC, (AU min)\] and expressed in units (U), where 10 AU min corresponds to 1 U \[[@CR15]\].

VerifyNow (VN) Aspirin™ blood samples were collected in anticoagulant-coated tubes with 3.2% sodium citrate (Vacutainer™), which were placed inside a cartridge for the assay. Reading occurred in the automated system after 5 min, and the results are described in aspirin reactivity units (ARUs).

Serum thromboxane B2 (TXB2) was measured to assess COX1 (also known as prostaglandin G/H synthase 1) inhibition by aspirin. The blood was collected in tubes without anticoagulant and incubated for 1 h, allowing the whole blood to clot and generate thrombin. The serum was then stored at − 80 °C and measured in duplicate by ELISA (Cayman Chemical, Michigan, EUA) according to the manufacturer's instructions.

In order to test for an adequate anticoagulation response, coagulation assays and kinetics regarding clot formation (coagulation time and clot formation time) and clot strength (maximum clot firmness) were studied with free oscillation rheometry (FOR), assessed with the ReoRox G2^®^ rheometer (Medirox AB, Nyköping, Sweden). FOR utilizes an oscillating movement to monitor coagulation. The sample is added to a reaction chamber, which consists of a gold-coated sample cup with a gold-coated cylinder (bob) suspended in the blood sample. FOR uses a torsion wire system to set the sample into oscillation. A magnet pulls back the measuring head connected to the torsion wire. On release, the torsion wire will set the cup into free oscillation and its movement is recorded by an optical detector. The changes of damping and frequency of the oscillation correlate to viscosity and elasticity, respectively, which are recorded as a viscosity curve and an elasticity curve.

Study Objectives {#Sec5}
----------------

The primary objective of the study was to compare dabigatran and enoxaparin regarding platelet aggregation using the MEA-ASPI test. The secondary objectives included the same evaluation with additional platelet function tests, namely, MEA-TRAP, TXB2, and VN Aspirin™ assays and coagulation tests. Additionally, the individual effects of enoxaparin and dabigatran on platelet aggregation were assessed by the MEA-ASPI test and compared to baseline values.

Statistical Analysis {#Sec6}
--------------------

The sample size was calculated assuming a difference between the drugs of 34% in the value of platelet aggregation, according to a previous publication \[[@CR4]\]. A statistical significance level of 95% was estimated, as well as a power of 80% and a loss to follow-up of 10%, for a sample size of 28 patients.

Categorical variables are described as absolute numbers or percentages and were compared using the chi-square test or Fisher's exact test, as appropriate. Continuous variables are described with their respective mean and standard deviations (assuming a Gaussian distribution) or their median values and 25th and 75th percentiles. The Kolmogorov--Smirnov test was used to evaluate normality. The paired Student's *t* test (normal distribution) or Wilcoxon (non-Gaussian distribution) test was used to compare platelet function between the groups.

The statistical analyses were performed using SPSS 17.0 (Microsoft, Chicago, USA), and the level of significance was defined as *p* \< 0.05.

Results {#Sec7}
=======

From the Acute Coronary Disease Unit databank, we retrospectively evaluated 86 patients which, accordingly to the available variables, were potential candidates for the study. As Fig. [2](#Fig2){ref-type="fig"} shows, 31 patients were initially selected; two of them met the exclusion criteria after the baseline visit because of platelet count (\< 100,000/mm^3^) and moderate renal insufficiency (creatinine clearance \< 50 ml/min).Fig. 2Enrollment and treatment

The baseline patient characteristics showed a mean age of 63 ± 8 years, and 69% were male. Regarding their medical history, 79.3% had arterial hypertension, and 48% were diabetic, with a median HbA1c of 6.2%. All patients had previous MI, the majority non-STEMI, and 75% had previously undergone a PCI. All patients were on statins, and 89.7% were taking beta-blockers (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristicsVariablesPatients (*n* = 29)Characteristics  Male (%)20 (69%)  Age\* (years)63 ± 8  BMI\* (kg/m^2^)29 ± 4  SBP\* (mmHg)130 ± 25  DBP^†^ (mmHg)80 (70--90)  HR\*65 ± 8Medical history  CKD (%)4 (13.8%)  DM (%)14 (48.3%)  Hypertension (%)23 (79.3%)  DLP (%)25 (86.2%)  Tobacco use (%)11 (37.9%)  Previous PCI (%)22 (75.9%)  Previous CABG (%)8 (27.6%)  STEMI (%)13 (44.8%)  NSTEMI (%)16 (55.2%)Laboratory exams  HbA1c^†^ (%)6.2 (5.9--7.5)  Hemoglobin^†^ (g/dl)14.6 (14.4--15.8)  Leukocytes\*/mm^3^7128 ± 1750  Creatinine\* (mg/dl)1.06 ± 0.23  BUN^†^ (mg/dl)34 (29--38)  ALP^†^ (mg/dl)35 (28--44)  AST^†^ (mg/dl)24 (20--28)  Glucose^†^ (mg/dl)114 (108--137)  Cholesterol^†^ (mg/dl)147 (124--178)  HDL\* (mg/dl)39.79 ± 10.95  LDL^†^ (mg/dl)75 (59--110)  Triglycerides^†^ (mg/dl)111 (103--205)Medications  Statin (%)29 (100%)  Beta-blocker (%)26 (89.7%)  ACE inhibitor (%)19 (65.5%)  Metformin (%)12 (41.4%)  Insulin (%)6 (20.7%)*BMI* body mass index, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *HR* heart rate, *bpm* beats per minute, *CKD* chronic kidney disease, *DM* diabetes mellitus, *DLP* dyslipidemia, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass graft, *STEMI* ST-segment elevation myocardial infarction, *NSTEMI* non-ST-segment elevation myocardial infarction, *ACE* angiotensin-converting enzyme inhibitor, *HbA1c* glycated hemoglobin, *LDL* low-density lipoprotein, *HDL* high-density lipoprotein\*Mean and SD^†^Median and (25th--75th percentiles)

Primary Objective {#Sec8}
-----------------

The DTI dabigatran increased platelet aggregability by 5 U ± 24.1 when compared to the anti-Xa enoxaparin, which decreased platelet aggregability by 6 U ± 22.2 (*p* = 0.012, 95% CI 2.4--18.1), with respect to the baseline values, as measured by MEA-ASPI test (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Platelet aggregation and activation differences from baseline for dabigatran and enoxaparin

Secondary Objectives {#Sec9}
--------------------

Likewise the MEA-ASPI results in Fig. [3](#Fig3){ref-type="fig"} show a significant difference between both therapy groups regarding serum TXB2 levels, which increased with dabigatran and decreased with enoxaparin (+ 2 pg/ml for dabigatran vs − 13 pg/ml for enoxaparin, *p* = 0.011).

Figure [4](#Fig4){ref-type="fig"} shows the results of the comparison between baseline and after treatment for each drug studied, considering different tests: for MEA-ASPI, there was no statistically significant difference for dabigatran or enoxaparin; on the other hand, TXB2 levels were significantly reduced after enoxaparin treatment compared to baseline \[20 (10--52) pg/ml after treatment versus 33 (16.5--95) pg/ml at baseline, *p* = 0.026\], but no significant differences were observed with dabigatran \[33 (16.5--95) pg/ml versus 35 (19.5--90), *p* = 0.602\]; for the other tests, Table [2](#Tab2){ref-type="table"} shows that MEA-TRAP and VN Aspirin™ presented no differences in platelet aggregation between the groups.Fig. 4Individual platelet aggregation changes from baseline when compared to dabigatran and to enoxaparin. **a** Thromboxane B2 test comparing median; **b** MEA-ASPI test comparing meansTable 2Comparison of other platelet aggregation testsBaselineDabigatranEnoxaparin*p*T0--TdT0--TXaTd--TXaMEA-ASPI\* (U)39.6 ± 2143.9 ± 2433.6 ± 220.3450.1600.012TXB2^†^ (pg/ml)33 (16.5--95)35 (19.5--90)20 (10--52)0.6020.0260.011VN ASPIRIN\* (ARU)543 ± 73544 ± 75530 ± 600.3750.2900.231MEA-TRAP\* (U)102 ± 26102 ± 22105 ± 390.7460.7660.728*T0* baseline, *Td* after dabigatran, *TXa* after enoxaparin, *TXB2* thromboxane B2, *VN* VerifyNow, *MEA-TRAP* multiplate electrode aggregometry with thrombin receptor-activating peptide 6 agonist\*Mean and SD^†^Median and (25th--75th percentiles)

Regarding the blood coagulation tests (Table [3](#Tab3){ref-type="table"}), the comparison between dabigatran and enoxaparin showed significant differences for all the analyzed parameters, with a more pronounced effect of dabigatran on mean activated partial thromboplastin time, international normalized ratio for prothrombin time, coagulation time, and clot formation time (all *p* values \< 0.0001); and a less pronounced dabigatran effect on the maximum clot firmness (*p* = 0.027).Table 3Comparison of main coagulation testsBaselineDabigatranEnoxaparin*p*T0--TdT0--TXaTd--TXaaPTT\* (ratio)1.01 ± 0.111.95 ± 0.51.35 ± 0.18\< 0.001\< 0.001\< 0.001INR^†^1.0 (1--1.1)1.3 (1.2--1.5)1.0 (1--1.1)\< 0.0010.071\< 0.001CT (s)\*31 ± 895 ± 3530.7 ± 8\< 0.0010.741\< 0.001CFT (s)\*87 ± 22175 ± 5180 ± 21\< 0.0010.159\< 0.001MCF (Pa)\*1707 ± 4911796 ± 3861999 ± 5270.3770.0200.027*T0* baseline, *Td* after dabigatran, *TXa* after enoxaparin, *aPTT* activated partial thromboplastin time, *INR* international normalized ratio for prothrombin time, *CT* coagulation time, *CFT* clot formation time, *MCF* maximum clot firmness (normal range = 1039 to 2825 Pa)\*Mean and SD^†^Median and (25th--75th percentiles)

Discussion {#Sec10}
==========

In this study, an increase in platelet aggregation was observed after dabigatran treatment compared to enoxaparin treatment in patients with CAD on aspirin, as assessed by the MEA-ASPI test.

The effects of dabigatran on platelet function and clinical outcomes have been a matter of concern since several trials suggested increased MI and/or ischemia with the use of the drug \[[@CR1], [@CR9], [@CR10], [@CR16], [@CR17]\]. Additionally, evidence also suggests that small DTI, such as dabigatran and bivalirudin, could increase the risk of thrombosis \[[@CR18], [@CR19]\].

Nevertheless, it is important to emphasize that no significant effect of dabigatran on platelet aggregation was found when compared to baseline, as assessed by different methods. This finding could be due to the concomitant use of aspirin, as shown in other trials of antiplatelet therapy and the use of new orallly administered anticoagulants, with no significant effect on platelet function \[[@CR20], [@CR21]\].

On the other hand, recent data have shown that dabigatran increases platelet reactivity by increasing the thrombin receptor density on platelets, as measured by platelet thrombin receptor expression \[[@CR22]\]. These findings were not confirmed in the present study, since no significant differences were noticed in platelet aggregation after treatment with dabigatran or enoxaparin when the TRAP receptor level (MEA-TRAP test) was assessed. This last result is also in accordance with the clinical setting, where different observational trials have suggested the safety of dabigatran in patients with AF \[[@CR23], [@CR24]\]. In addition, in patients with nonvalvular AF undergoing PCI, the RE-DUAL PCI trial evaluated dual antithrombotic therapy with dabigatran and a P2Y~12~ inhibitor versus triple therapy with warfarin plus DAPT and found no differences between the groups regarding thromboembolic events. Although the absolute number of MIs was higher for both doses of dabigatran, with 44 patients (4.5%) in the 110-mg dual-therapy group compared with 29 (3%) in the triple-therapy group and 26 patients (3.4%) in the 150-mg dual-therapy group compared with 22 (2.9%) in the corresponding triple-therapy group, the observed differences between groups did not reach statistical significance \[[@CR25]\].

Finally, this study's data on enoxaparin shows a reduction in platelet activation by MEA-ASPI and TXB2 when compared with baseline, with similar results for dabigatran, as tested with the TXB2 assay. This result may be due to different mechanisms of action, such as decreasing the ability of platelets to bind fibrinogen (glycoprotein IIb/IIIa activation) and express P-selectin in response to adenosine diphosphate \[[@CR26], [@CR27]\]. In contrast, this study's results could not be reproduced in a clinical setting as, compared to dabigatran, enoxaparin did not reduce myocardial ischemic events in different trials reported in a metanalysis by Douxfils et al. \[[@CR9]\].

Regarding coagulation tests, the present results are in compliance with the literature, as dabigatran, but not enoxaparin, prolonged the aPTT, thus increasing the aPTT ratio. It is important to notice that aPTT may provide a qualitative assessment of the dabigatran level and activity by a curvilinear relation and is a considerable tool for guiding dabigatran reversal \[[@CR28], [@CR29]\].

Concerning the coagulation kinetics, this study's findings are consistent with previous data that show a significant linear correlation between the clotting time and dabigatran concentration, which might be useful for anticoagulation monitoring and emergency management \[[@CR30]\].

Study Limitations {#Sec11}
-----------------

This study's results should be interpreted considering the specific characteristics of the population composed of patients with chronic CAD on aspirin. Therefore, the results should not be extrapolated to patients with DAPT indications or populations with AF not taking aspirin. In addition, this was a mechanistic study evaluating a surrogate outcome. Thus, it is not possible to make definitive conclusions regarding the clinical impact of the findings.

Conclusion {#Sec12}
==========

No significant differences in platelet aggregation were observed with dabigatran compared to baseline in patients with CAD on aspirin, reinforcing its safety in terms of final platelet activity. However, when tested against the anti-Xa effect of enoxaparin, dabigatran increased platelet activation and aggregation promoted by thromboxane. Furthermore, enoxaparin showed a significant decrease in platelet activation by COX1 when analyzed by TXB2.
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